Approval · Notice of Compliance 15353 · 2014
RAN-MEMANTINE: Notice of Compliance 15353
Issued February 27, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15353
- Date
- February 27, 2014
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- N-methyl-D-aspartate (nmda) rececptor inhibitor
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAN-MEMANTINE | 02421364 | Cancelled Post Market |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 10 MG per TAB